Physician profile
Daisy Li
NPI 1740770007
$15,885.90
in general payments reported to CMS, 2019-2025
46 companies · $4,138 in 2025
The $4,138 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $626 · 2022: $2,843 · 2023: $3,832 · 2024: $4,448 · 2025: $4,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,296.95 |
| Education | $120.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,135.85 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Gilead Sciences, INC. | $1,193.10 | 2021-2025 | Vemlidy |
| Amgen INC. | $1,144.10 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Lilly USA, LLC | $1,028.61 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,011.11 | 2021-2025 | Ozempic, Rybelsus |
| Vifor Pharma, INC. | $922.21 | 2021-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $844.53 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Otsuka America Pharmaceutical, INC. | $802.33 | 2021-2025 | Jynarque, Rexulti, Voyxact |
| Travere Therapeutics, INC. | $689.14 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $658.32 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $646.51 | 2021-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $588.21 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $502.58 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $408.67 | 2022-2025 | Acthar |
| Horizon Therapeutics Plc | $372.34 | 2021-2023 | Krystexxa |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.